Vaccination with Fendrix of prior nonresponding patients with HIV has a high success rate

Julian D. Machiels; Esmee E. Braam; Petra van Bentum; Michele van Vugt; Theodora E. M. S. de Vries-Sluijs; Ineke W. E. M. Schouten; Wouter F. W. Bierman; Elisabeth H. Gisolf

doi:10.1097/QAD.0000000000002085

Vaccination with Fendrix of prior nonresponding patients with HIV has a high success rate

Julian D. Machiels^*, Esmee E. Braam, Petra van Bentum, Michele van Vugt, Theodora E. M. S. de Vries-Sluijs, Ineke W. E. M. Schouten, Wouter F. W. Bierman, Elisabeth H. Gisolf

^*Corresponding author voor dit werk

Onderzoeksoutput › Academic › peer review

12 Citaten (Scopus)

25 Downloads (Pure)

Samenvatting

Background: Patients with HIV have a poor serological conversion rate with the standard vaccination strategy against hepatitis B virus (HBV) of around 50%. Vaccination with Fendrix confers much better results in these patients. In this study, we tested the effect of revaccination with Fendrix in prior nonresponding patients with HIV and aimed to determine which factors are associated with seroconversion.

Methods: Eight Dutch HIV treatment centers participated in this retrospective study. Patients infected with HIV-1 and nonresponding to prior course of vaccination against HBV (anti-HBs

Results: We included 100 patients with HIV. The mean age was 47.3 (+/- 11.0) years and 86% were men. Revaccination with Fendrix showed a seroconversion rate of 81% (95% confidence interval 72-88%). Median nadir CD4(+) cell count was 300 (20-1040) cells/ml and median CD4(+) cell count at the time at starting vaccination with Fendrix was 605 (210-1190) cells/ml. Regression analyses showed no significant factor associated with seroconversion.

Conclusions: Revaccination with Fendrix of patients prior nonresponding to other hepatitis B vaccination strategies has a high success rate. Eighty-one percentage responded with seroconversion, irrespective of CD4(+) cell count. Copyright (C) 2018 Wolters Kluwer Health, Inc. All rights reserved.

Originele taal-2	English
Pagina's (van-tot)	503-507
Aantal pagina's	5
Tijdschrift	Aids
Volume	33
Nummer van het tijdschrift	3
DOI's	https://doi.org/10.1097/QAD.0000000000002085
Status	Published - 1-mrt.-2019

Toegang tot document

10.1097/QAD.0000000000002085

Vaccination with Fendrix of prior nonresponding patients with HIV has a high success rateFinal publisher's version, 143 KBLicentie: Taverne

Handle.net

Permanente koppeling

Citeer dit

@article{26a1682aeb184da6b41c71f9702aeada,

title = "Vaccination with Fendrix of prior nonresponding patients with HIV has a high success rate",

abstract = "Background: Patients with HIV have a poor serological conversion rate with the standard vaccination strategy against hepatitis B virus (HBV) of around 50%. Vaccination with Fendrix confers much better results in these patients. In this study, we tested the effect of revaccination with Fendrix in prior nonresponding patients with HIV and aimed to determine which factors are associated with seroconversion.Methods: Eight Dutch HIV treatment centers participated in this retrospective study. Patients infected with HIV-1 and nonresponding to prior course of vaccination against HBV (anti-HBsResults: We included 100 patients with HIV. The mean age was 47.3 (+/- 11.0) years and 86% were men. Revaccination with Fendrix showed a seroconversion rate of 81% (95% confidence interval 72-88%). Median nadir CD4(+) cell count was 300 (20-1040) cells/ml and median CD4(+) cell count at the time at starting vaccination with Fendrix was 605 (210-1190) cells/ml. Regression analyses showed no significant factor associated with seroconversion.Conclusions: Revaccination with Fendrix of patients prior nonresponding to other hepatitis B vaccination strategies has a high success rate. Eighty-one percentage responded with seroconversion, irrespective of CD4(+) cell count. Copyright (C) 2018 Wolters Kluwer Health, Inc. All rights reserved.",

keywords = "coinfection, hepatitis B, HIV, vaccination, vaccines, HEPATITIS-B-VIRUS, CD4/CD8 RATIO, REVACCINATION, ADULTS",

author = "Machiels, {Julian D.} and Braam, {Esmee E.} and {van Bentum}, Petra and {van Vugt}, Michele and {de Vries-Sluijs}, {Theodora E. M. S.} and Schouten, {Ineke W. E. M.} and Bierman, {Wouter F. W.} and Gisolf, {Elisabeth H.}",

year = "2019",

month = mar,

day = "1",

doi = "10.1097/QAD.0000000000002085",

language = "English",

volume = "33",

pages = "503--507",

journal = "Aids",

issn = "0269-9370",

publisher = "Lippincott Williams and Wilkins",

number = "3",

}

TY - JOUR

T1 - Vaccination with Fendrix of prior nonresponding patients with HIV has a high success rate

AU - Machiels, Julian D.

AU - Braam, Esmee E.

AU - van Bentum, Petra

AU - van Vugt, Michele

AU - de Vries-Sluijs, Theodora E. M. S.

AU - Schouten, Ineke W. E. M.

AU - Bierman, Wouter F. W.

AU - Gisolf, Elisabeth H.

PY - 2019/3/1

Y1 - 2019/3/1

N2 - Background: Patients with HIV have a poor serological conversion rate with the standard vaccination strategy against hepatitis B virus (HBV) of around 50%. Vaccination with Fendrix confers much better results in these patients. In this study, we tested the effect of revaccination with Fendrix in prior nonresponding patients with HIV and aimed to determine which factors are associated with seroconversion.Methods: Eight Dutch HIV treatment centers participated in this retrospective study. Patients infected with HIV-1 and nonresponding to prior course of vaccination against HBV (anti-HBsResults: We included 100 patients with HIV. The mean age was 47.3 (+/- 11.0) years and 86% were men. Revaccination with Fendrix showed a seroconversion rate of 81% (95% confidence interval 72-88%). Median nadir CD4(+) cell count was 300 (20-1040) cells/ml and median CD4(+) cell count at the time at starting vaccination with Fendrix was 605 (210-1190) cells/ml. Regression analyses showed no significant factor associated with seroconversion.Conclusions: Revaccination with Fendrix of patients prior nonresponding to other hepatitis B vaccination strategies has a high success rate. Eighty-one percentage responded with seroconversion, irrespective of CD4(+) cell count. Copyright (C) 2018 Wolters Kluwer Health, Inc. All rights reserved.

AB - Background: Patients with HIV have a poor serological conversion rate with the standard vaccination strategy against hepatitis B virus (HBV) of around 50%. Vaccination with Fendrix confers much better results in these patients. In this study, we tested the effect of revaccination with Fendrix in prior nonresponding patients with HIV and aimed to determine which factors are associated with seroconversion.Methods: Eight Dutch HIV treatment centers participated in this retrospective study. Patients infected with HIV-1 and nonresponding to prior course of vaccination against HBV (anti-HBsResults: We included 100 patients with HIV. The mean age was 47.3 (+/- 11.0) years and 86% were men. Revaccination with Fendrix showed a seroconversion rate of 81% (95% confidence interval 72-88%). Median nadir CD4(+) cell count was 300 (20-1040) cells/ml and median CD4(+) cell count at the time at starting vaccination with Fendrix was 605 (210-1190) cells/ml. Regression analyses showed no significant factor associated with seroconversion.Conclusions: Revaccination with Fendrix of patients prior nonresponding to other hepatitis B vaccination strategies has a high success rate. Eighty-one percentage responded with seroconversion, irrespective of CD4(+) cell count. Copyright (C) 2018 Wolters Kluwer Health, Inc. All rights reserved.

KW - coinfection

KW - hepatitis B

KW - HIV

KW - vaccination

KW - vaccines

KW - HEPATITIS-B-VIRUS

KW - CD4/CD8 RATIO

KW - REVACCINATION

KW - ADULTS

U2 - 10.1097/QAD.0000000000002085

DO - 10.1097/QAD.0000000000002085

M3 - Article

SN - 0269-9370

VL - 33

SP - 503

EP - 507

JO - Aids

JF - Aids

IS - 3

ER -

Vaccination with Fendrix of prior nonresponding patients with HIV has a high success rate

Samenvatting

Toegang tot document

Handle.net

Vingerafdruk

Citeer dit